Cargando…

Gaucher Disease in Bone: From Pathophysiology to Practice

Gaucher disease (GD) is a rare, genetic lysosomal disorder leading to lipid accumulation and dysfunction in multiple organs. Involvement of the skeleton is one of the most prevalent aspects of GD and a major cause of pain, disability, and reduced quality of life. Uniform recommendations for contempo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hughes, Derralynn, Mikosch, Peter, Belmatoug, Nadia, Carubbi, Francesca, Cox, TimothyM, Goker‐Alpan, Ozlem, Kindmark, Andreas, Mistry, PramodK, Poll, Ludger, Weinreb, Neal, Deegan, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852006/ https://www.ncbi.nlm.nih.gov/pubmed/31233632 http://dx.doi.org/10.1002/jbmr.3734

Ejemplares similares

Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trials
por: Elstein, Deborah, et al.
Publicado: (2022)

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)
por: Zimran, Ari, et al.
Publicado: (2017)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Optimal therapy in Gaucher disease
por: Goker-Alpan, Ozlem
Publicado: (2010)

Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
por: Hughes, Derralynn A., et al.
Publicado: (2023)

Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative
por: Mehta, Atul, et al.
Publicado: (2019)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
por: Schwartz, Ida Vanessa D., et al.
Publicado: (2017)

Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis
por: Mistry, Pramod K, et al.
Publicado: (2009)

Clinical course and prognosis in patients with Gaucher disease and parkinsonism
por: Lopez, Grisel, et al.
Publicado: (2016)

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability
por: Pastores, Gregory M., et al.
Publicado: (2014)

The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
por: Mistry, Pramod K., et al.
Publicado: (2023)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease
por: Limgala, Renuka P., et al.
Publicado: (2020)

The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients
por: Deegan, Patrick, et al.
Publicado: (2021)

Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
por: Mistry, Pramod, et al.
Publicado: (2020)

Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases
por: Ivanova, Margarita M., et al.
Publicado: (2019)

Hepatocellular carcinoma in Gaucher disease: an international case series
por: Regenboog, Martine, et al.
Publicado: (2018)

TRAP5b and RANKL/OPG Predict Bone Pathology in Patients with Gaucher Disease
por: Ivanova, Margarita, et al.
Publicado: (2021)

A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
por: Stirnemann, Jérôme, et al.
Publicado: (2017)

Biofabrication of an in-vitro bone model for Gaucher disease
por: Banerjee, Dishary, et al.
Publicado: (2023)

COVID-19 patient impact: A survey of the Gaucher community involving patients, caregivers and family members based in the US to determine impact of the pandemic
por: Ryan, Emory, et al.
Publicado: (2021)

Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials
por: Lukina, Elena, et al.
Publicado: (2020)

Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model
por: Vigan, Marie, et al.
Publicado: (2014)

Imiglucerase in the treatment of Gaucher disease: a history and perspective
por: Deegan, Patrick B, et al.
Publicado: (2012)

Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease
por: Limgala, Renuka Pudi, et al.
Publicado: (2016)

In-depth phenotyping for clinical stratification of Gaucher disease
por: D’Amore, Simona, et al.
Publicado: (2021)

Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease
por: Ivanova, Margarita M., et al.
Publicado: (2022)

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2017)

Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease
por: Ivanova, Margarita M., et al.
Publicado: (2021)

Phagocytosis of Erythrocytes from Gaucher Patients Induces Phenotypic Modifications in Macrophages, Driving Them toward Gaucher Cells
por: Dupuis, Lucie, et al.
Publicado: (2022)

Splenic Artery Aneurysms, a Rare Complication of Type 1 Gaucher Disease: Report of Five Cases
por: Serratrice, Christine, et al.
Publicado: (2019)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Lessons from lung transplantation: Cause for redefining the pathophysiology of pulmonary hypertension in gaucher disease
por: Goobie, Gillian C., et al.
Publicado: (2019)

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
por: Pleat, Rebecca, et al.
Publicado: (2016)

Type 3 Gaucher disease, diagnostic in adulthood
por: Detollenaere, Charles, et al.
Publicado: (2017)

Bone events and evolution of biologic markers in Gaucher disease before and during treatment
por: Stirnemann, Jérôme, et al.
Publicado: (2010)

Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease
por: Lefebvre, Thibaud, et al.
Publicado: (2018)

The mutation spectrum in Indian patients with Gaucher disease
por: Bisariya, Vartika, et al.
Publicado: (2011)

Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites in Gaucher Disease
por: Adhyaru, Kunal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7iup71526d7jsj8n9jetu7ahck